Clinical Trial Evidence: What the Data Shows for Both Options
Mounjaro or Wegovy Weight Loss Results: Understanding the Clinical Evidence
When comparing Mounjaro or Wegovy weight loss results, both medications have demonstrated substantial efficacy in peer-reviewed clinical trials. Wegovy's STEP programme showed remarkable outcomes, with participants achieving approximately 15% average weight loss at 68 weeks when combined with lifestyle interventions. The STEP 3 trial, incorporating intensive behavioural therapy, demonstrated even higher results at around 16% average weight reduction. Importantly, these results represent what patients achieved in controlled clinical settings alongside diet and exercise modifications.
Mounjaro's clinical evidence comes from the SURMOUNT trials, where tirzepatide's dual mechanism targeting both GIP and GLP-1 receptors showed impressive outcomes. However, direct comparisons between Mounjaro or Wegovy results require careful consideration of different trial designs and patient populations. Both prescription-only medicines work through distinct pathways—Wegovy as a GLP-1 receptor agonist and Mounjaro as a dual GIP/GLP-1 agonist. The choice between these options depends on individual patient factors that our prescribers evaluate during clinical assessment.
Wegovy Pricing and Value: Complete UK Cost Breakdown
Understanding the investment in Mounjaro or Wegovy treatment helps inform your decision. Wegovy pricing at EverydayMeds starts with our 0.25mg starter dose at £79.99, progressing through 0.5mg (£94.99), 1mg (£99.99), 1.7mg (£139.99), to the 2.4mg maintenance dose (£209.99). New customers benefit from our FIRST40 discount code applied at checkout, whilst returning customers use DOSE25. Our bundled options provide convenience for multi-month supplies without the need for frequent reordering.
Our Getting Started bundles streamline the initial dose escalation process, with the Intro Duo (0.25mg & 0.5mg) at £169.99 and Progress Duo (0.5mg & 1mg) at £189.99. For those requiring consistency at maintenance doses, our Stay Steady bundles offer paired supplies, such as Consistency 2.4mg (×2) at £419.99. These bundled approaches ensure uninterrupted treatment continuity, which clinical evidence suggests is crucial for sustained weight management outcomes. All prices include our comprehensive service encompassing clinical assessment, prescriber review, and temperature-controlled delivery.
STEP Trial Results: Published Evidence for Wegovy Efficacy
The landmark STEP trials, published by Wilding et al. in the New England Journal of Medicine (2021), provide robust evidence for Wegovy's effectiveness. STEP 1 demonstrated that patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss over 68 weeks, compared to 2.4% with placebo. The trial's rigorous methodology included participants with BMI ≥30 or BMI ≥27 with weight-related comorbidities.
Long-term sustainability data from STEP 5 showed maintained weight loss of approximately 15.2% at two years, addressing concerns about treatment durability. Additionally, the SELECT cardiovascular outcomes trial demonstrated a 20% reduction in major cardiovascular events, highlighting benefits beyond weight management. When considering Mounjaro or Wegovy options, these published results provide confidence in evidence-based treatment selection.
How Wegovy Works: GLP-1 Mechanism Explained
Wegovy functions as a GLP-1 receptor agonist, mimicking the action of a natural hormone called glucagon-like peptide-1 that regulates appetite and food intake. This mechanism reduces hunger signals sent to the brain whilst promoting feelings of fullness after smaller meals, supporting portion control and reduced caloric intake. The medication may also influence food cravings and the reward pathways associated with eating, contributing to sustained behavioural changes. Unlike rapid-acting appetite suppressants, Wegovy's effects develop gradually through the dose escalation protocol, allowing patients to adapt to new eating patterns. This biological approach to weight management works most effectively when combined with nutritional guidance and increased physical activity, creating a comprehensive treatment framework. The once-weekly injection format using Novo Nordisk's FlexTouch pen system ensures consistent medication levels throughout the week.
EverydayMeds Ordering Process: From Assessment to Delivery
Accessing Mounjaro or Wegovy through EverydayMeds begins with our streamlined 3-minute online clinical assessment, designed to gather essential medical history and current health status information. Our UK-registered prescribers (GPhC #9012878) review each application within 3 working days as standard, with express 24-hour review available for urgent requirements. The assessment evaluates BMI criteria, weight-related comorbidities, previous weight management attempts, and potential contraindications to ensure appropriate prescribing. Once approved, medications are dispatched via next-day delivery using specialised cold-chain logistics to maintain the required 2-8°C temperature throughout transit. Our pharmacy team coordinates delivery timing to ensure someone is available to receive temperature-sensitive medications, preventing exposure to unsuitable storage conditions. This comprehensive service eliminates the complexity often associated with accessing prescription weight management treatments privately.
Storage and Practical Considerations: Mounjaro or Wegovy Handling
Storage requirements represent a key practical difference when choosing between Mounjaro or Wegovy options. Wegovy pens must be stored in the refrigerator at 2-8°C before first use but offer significant flexibility with 6 weeks of room temperature stability once removed from refrigeration, provided temperatures don't exceed 30°C. This extended room temperature tolerance makes Wegovy particularly suitable for frequent travellers or those with variable schedules. In contrast, Mounjaro provides 21 days of room temperature stability, requiring more careful planning for extended periods away from refrigeration. The FlexTouch pen system used for Wegovy features intuitive dose selection and injection mechanisms, with clear dosage windows and audible click confirmations. Dose escalation follows a mandatory schedule starting at 0.25mg for weeks 1-4, preventing gastrointestinal side effects associated with rapid dose increases, and patients cannot skip escalation steps without clinical justification.
UK Patient Outcomes: Real-World Mounjaro or Wegovy Results Data
Post-marketing surveillance data from UK patients using Mounjaro or Wegovy provides insight into real-world effectiveness beyond controlled trial conditions. NHS England's specialist weight management services report positive outcomes when these medications are integrated with comprehensive lifestyle support programmes. However, individual results vary significantly based on baseline characteristics, adherence to dietary modifications, exercise engagement, and concurrent medical conditions. The importance of realistic expectation setting cannot be overstated, as clinical trials represent optimal conditions with intensive support structures.
UK prescribing data indicates that both medications require long-term commitment for sustained benefits, with weight regain typically occurring when treatment discontinues. STEP trial extension data showed patients regained approximately two-thirds of lost weight within one year of stopping Wegovy, emphasising that weight management represents an ongoing medical condition rather than a short-term intervention. Our clinical team at EverydayMeds provides ongoing support to help patients understand this chronic disease management approach.
Making Your Choice: Mounjaro or Wegovy Decision Framework
Selecting between Mounjaro or Wegovy requires individualised assessment considering multiple factors beyond clinical trial results. Both medications are available through EverydayMeds, and our prescribers can help determine which option aligns with your specific circumstances, medical history, and treatment goals. Starting at £79.99 with our discount codes applied at checkout, either treatment represents a significant investment in long-term health outcomes. Our clinical assessment process evaluates factors such as previous medication responses, lifestyle considerations, and treatment preferences to guide appropriate selection. Complete your assessment today at https://everydaymeds.co.uk/collections/wegovy to begin your evidence-based weight management journey with expert clinical support throughout your treatment experience. Both options require prescription-only medicine protocols ensuring safe, supervised use under qualified medical oversight.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
